Metsera (MTSR) Competitors $33.05 +0.25 (+0.76%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock MTSR vs. VTRS, RDY, ASND, QGEN, MRNA, BBIO, VRNA, ELAN, BPMC, and ROIVShould you be buying Metsera stock or one of its competitors? The main competitors of Metsera include Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Qiagen (QGEN), Moderna (MRNA), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Blueprint Medicines (BPMC), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Metsera vs. Its Competitors Viatris Dr. Reddy's Laboratories Ascendis Pharma A/S Qiagen Moderna BridgeBio Pharma Verona Pharma PLC American Depositary Share Elanco Animal Health Blueprint Medicines Roivant Sciences Viatris (NASDAQ:VTRS) and Metsera (NASDAQ:MTSR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability. Does the media refer more to VTRS or MTSR? In the previous week, Viatris had 1 more articles in the media than Metsera. MarketBeat recorded 4 mentions for Viatris and 3 mentions for Metsera. Metsera's average media sentiment score of 0.37 beat Viatris' score of 0.00 indicating that Metsera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Metsera 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate VTRS or MTSR? Viatris presently has a consensus target price of $10.40, suggesting a potential downside of 2.35%. Metsera has a consensus target price of $55.00, suggesting a potential upside of 66.41%. Given Metsera's stronger consensus rating and higher possible upside, analysts plainly believe Metsera is more favorable than Viatris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viatris 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80Metsera 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is VTRS or MTSR more profitable? Metsera has a net margin of 0.00% compared to Viatris' net margin of -24.57%. Viatris' return on equity of 16.54% beat Metsera's return on equity.Company Net Margins Return on Equity Return on Assets Viatris-24.57% 16.54% 7.06% Metsera N/A N/A N/A Do insiders & institutionals believe in VTRS or MTSR? 79.9% of Viatris shares are held by institutional investors. 0.1% of Viatris shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has preferable valuation and earnings, VTRS or MTSR? Metsera has lower revenue, but higher earnings than Viatris. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViatris$14.74B0.84-$634.20M-$2.90-3.67MetseraN/AN/A-$209.13MN/AN/A SummaryViatris and Metsera tied by winning 6 of the 12 factors compared between the two stocks. Get Metsera News Delivered to You Automatically Sign up to receive the latest news and ratings for MTSR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MTSR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTSR vs. The Competition Export to ExcelMetricMetseraMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.47B$3.09B$5.82B$9.74BDividend YieldN/A2.23%3.84%4.09%P/E RatioN/A21.1431.1525.97Price / SalesN/A399.83475.57123.18Price / CashN/A43.0937.1558.38Price / Book7.728.079.116.39Net Income-$209.13M-$54.72M$3.26B$265.66M7 Day Performance6.13%2.62%2.11%1.98%1 Month Performance-16.22%7.63%5.12%1.33%1 Year PerformanceN/A13.11%31.25%21.15% Metsera Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTSRMetseraN/A$33.05+0.8%$55.00+66.4%N/A$3.47BN/A0.0081Positive NewsVTRSViatris1.6948 of 5 stars$10.61-0.7%$10.40-2.0%-8.8%$12.46B$14.74B-3.6632,000RDYDr. Reddy's Laboratories3.129 of 5 stars$14.22+0.8%$16.95+19.2%-14.5%$11.78B$3.81B21.5527,811Positive NewsASNDAscendis Pharma A/S3.3407 of 5 stars$198.32+3.3%$242.93+22.5%+40.7%$11.74B$490.75M-38.431,017News CoveragePositive NewsAnalyst ForecastQGENQiagen3.8337 of 5 stars$49.36+0.8%$49.69+0.7%+7.4%$10.88B$1.98B29.165,765MRNAModerna4.4427 of 5 stars$28.02+5.0%$43.59+55.6%-69.7%$10.38B$3.24B-3.725,800Analyst ForecastBBIOBridgeBio Pharma4.7461 of 5 stars$51.32+0.3%$61.35+19.5%+96.5%$9.78B$221.90M-12.55400Insider TradeVRNAVerona Pharma PLC American Depositary Share2.4678 of 5 stars$105.27flat$109.00+3.5%+276.7%$8.96B$42.28M-106.3330Positive NewsShort Interest ↓ELANElanco Animal Health3.1498 of 5 stars$17.97-0.2%$17.33-3.5%+17.8%$8.94B$4.44B20.909,000Positive NewsAnalyst DowngradeBPMCBlueprint Medicines0.5049 of 5 stars$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640ROIVRoivant Sciences3.4873 of 5 stars$11.85+0.9%$16.50+39.2%+0.2%$7.99B$29.05M-16.93860 Related Companies and Tools Related Companies VTRS Alternatives RDY Alternatives ASND Alternatives QGEN Alternatives MRNA Alternatives BBIO Alternatives VRNA Alternatives ELAN Alternatives BPMC Alternatives ROIV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MTSR) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metsera Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metsera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access